Reflecting heterogeneity in patient benefits: The role of subgroup analysis with comparative effectiveness

Value in Health

Volumn 13, Issue SUPPL. 1, 2010, Pages

  Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

heterogeneity; net benefit; QALYs; subgroups

Indexed keywords

ENOXAPARIN; FONDAPARINUX;

COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HUMAN; PRIORITY JOURNAL; RESEARCH SUBJECT; SHORT SURVEY; SUBGROUP ANALYSIS;

EID: 77954344090     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00750.x     Document Type: Short Survey

References (7)

1. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006 354 : 1464 1476.
2. Garrison LP, Towse A, Bresnahan BW. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff 2007 26 : 684 695.
3. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evalaution of Health Care Programmes.
4. Sculpher MJ, Lozano-Ortega G, Sambrook J, et al. Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J 2009 157 : 845 852.
5. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ 2004 328 : 371.
6. Sculpher M. The cost-effectiveness of preference-based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia. Health Econ 1998 7 : 129 142. (Pubitemid 28163781)
7. Ryan M, Gerard K, Amaya-Amaya M. Using Discrete Choice to Value Health and Health Care.